• 1. An assessment of strategies for the development of solid-state adsorbents for vehicular hydrogen storage
  Mark D. Allendorf,Alauddin Ahmed,Tom Autrey,Jeffrey Camp,Eun Seon Cho,Maciej Haranczyk,Abhi Karkamkar,Di-Jia Liu,Katie R. Meihaus,Iffat H. Nayyar,Roman Nazarov,Donald J. Siegel,Vitalie Stavila,Jeffrey J. Urban,Srimukh Prasad Veccham,Brandon C. Wood Energy Environ. Sci., 2018,11, 2784-2812
• 2. An integrated system for field analysis of Cd(ii) and Pb(ii) via preconcentration using nano-TiO2/cellulose paper composite and subsequent detection with a portable X-ray fluorescence spectrometer?
  Xiaofeng Lin RSC Adv., 2016,6, 9002-9006
• 3. An intensified π-hole in beryllium-doped boron nitride meshes: its determinant role in CO2 conversion into hydrocarbon fuels?
  Luis Miguel Azofra,Douglas R. MacFarlane,Chenghua Sun Chem. Commun., 2016,52, 3548-3551
• 4. An aptasensor for the detection of ampicillin in milk using a personal glucose meter
  Xixi Li,Nanwei Zhu,Ruohan Li,Qinpu Zhang Anal. Methods, 2020,12, 3376-3381
• 5. An insight into the origin of room-temperature ferromagnetism in SnO2 and Mn-doped SnO2 quantum dots: an experimental and DFT approach?
  Dhamodaran Manikandan,S. Amirthapandian,I. S. Zhidkov,A. I. Kukharenko,S. O. Cholakh,Ramaswamy Murugan Phys. Chem. Chem. Phys., 2018,20, 6500-6514

Professional Introduction to 5-Bromo-2-ethyl-2H-indazole (CAS No. 590417-97-3)

5-Bromo-2-ethyl-2H-indazole is a heterocyclic organic compound that has garnered significant attention in the field of pharmaceutical chemistry and medicinal research. This compound, identified by its Chemical Abstracts Service (CAS) number CAS No. 590417-97-3, belongs to the indazole class of molecules, which are known for their diverse biological activities and potential therapeutic applications. The structural features of 5-Bromo-2-ethyl-2H-indazole, particularly the presence of a bromine substituent at the 5-position and an ethyl group at the 2-position, contribute to its unique chemical properties and reactivity, making it a valuable scaffold for further chemical modifications and biological evaluations.

The indazole core is a fused bicyclic system consisting of a benzene ring and a pyrazole ring, which is a common motif in many bioactive natural products and synthetic drugs. The bromine atom at the 5-position of the indazole ring enhances the electrophilicity of the molecule, facilitating various nucleophilic substitution reactions that are commonly employed in drug discovery and development. Additionally, the ethyl group at the 2-position introduces steric hindrance and influences the electronic properties of the molecule, which can be exploited to modulate its biological activity.

In recent years, there has been a growing interest in exploring the pharmacological potential of indazole derivatives due to their reported activities against various diseases, including cancer, infectious diseases, and neurological disorders. The brominated indazoles have been particularly studied for their ability to interact with biological targets such as kinases, transcription factors, and other enzymes involved in disease pathways. For instance, studies have shown that certain brominated indazole compounds exhibit inhibitory effects on tyrosine kinases, which are overexpressed in many cancer cell lines.

One of the most notable applications of 5-Bromo-2-ethyl-2H-indazole is in the development of novel antitumor agents. Researchers have leveraged its structural framework to design molecules that can selectively inhibit the growth of cancer cells by targeting specific signaling pathways. The bromine atom serves as a handle for further derivatization, allowing chemists to introduce additional functional groups that can enhance binding affinity and selectivity towards cancer-related proteins. Preclinical studies have demonstrated promising results with some indazole derivatives showing significant antiproliferative effects in vitro and in vivo.

The synthesis of 5-Bromo-2-ethyl-2H-indazole typically involves multi-step organic reactions starting from commercially available precursors. Common synthetic routes include bromination of an appropriately substituted indazole precursor followed by alkylation to introduce the ethyl group. The choice of reagents and reaction conditions is critical to achieving high yields and purity, which are essential for subsequent biological evaluations. Advanced techniques such as palladium-catalyzed cross-coupling reactions have also been employed to improve synthetic efficiency and regioselectivity.

The pharmacokinetic properties of 5-Bromo-2-ethyl-2H-indazole are another area of active investigation. Understanding how a compound is absorbed, distributed, metabolized, and excreted (ADME) is crucial for assessing its potential as a drug candidate. Preliminary studies suggest that this compound exhibits moderate solubility in water and lipids, which may influence its bioavailability and distribution within the body. Further research is needed to optimize its pharmacokinetic profile through structural modifications.

In conclusion, 5-Bromo-2-ethyl-2H-indazole (CAS No. 590417-97-3) represents a promising scaffold for pharmaceutical development with its unique structural features and potential biological activities. The presence of both bromine and ethyl substituents provides opportunities for diverse chemical modifications and biological evaluations. As research in this area continues to advance, it is likely that more derivatives will be developed with improved efficacy and safety profiles, contributing to the discovery of new therapeutic agents for various diseases.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)